Genetic profiling using whole genome sequencing (WGS) or whole exome sequencing (WES) is combined with RNA-sequencing for clinical molecular profiling of a patients tumour. A turnaround time of ten days makes genetics and transcriptomics combination a valuable service for patient stratification within clinical trials, neoantigen prediction for manufacturing of personalized cancer vaccines or adoptive cell therapy, and for personalized treatment decisions.

Solutions that require only a minimal sample input and solutions for archival tissues allow you to profile all your precious samples. Differentiating between somatic and germline aberrations can be achieved by performing a WGS or WES on both tumour and normal samples while RNAseq confirms expression of the aberrations of interest.